ImpediMed Ltd (ASX: IPD), which is engaged in the development and distribution of medical devices using Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of human disorders and disease, has moved an inch up with regards to its commercialisation plan and has progressed with the initial shipments of SOZO™systems with L-Dex®technology to customers in the US. The initial target for the first phase of commercial launch in the US is said to include existing customers. The platform has been an effective tool to connect devices at multiple locations and integrating the data into a single patient record. The group has been able to receive positive initial feedback from clinicians and existing customers who may add over U400. Many customers have indicated to expand the program from testing only high-risk breast cancer patients to all cancer survivors that are at risk of developing unilateral lymphedema in upper and lower extremities.   

Earlier this year, IPD had commenced its first commercial sales for the SOZO platform in Europe and Australia. The first customers to use SOZO have been said to be large hospitals, that connect devices to measure fluid and body indicators.

On October 23, 2017, IPD also announced about the publication of a study to date in a peer-reviewed medical journal (The Breast Journal) on the effectiveness of L-Dex for the screening, intervention and prevention of disease progression to irreversible stages. The company had indicated earlier that the study was to be conducted by Pat Whitworth, MD, of the Nashville Breast Centre. Primarily, a retrospective analysis was conducted to examine 596 prospectively surveilled breast cancer patients at-risk for the development of lymphoedema from April 2010 to Nov 2016. It was highlighted that only 18 patients (3%) had unresolved clinically BCRL (breast cancer related lymphoedema) requiring Complete Decongestive Physiotherapy (CDP), a surrogate for the development of clinically, chronic BCRL. In the month of August, IPD released about superior clinical outcomes using L-Dex®.

IPD stock has been up 1.4% on October 23, 2017 with the release of the positive update.

Disclaimer
 
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated pages are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.